TMCnet News
BeiGene to Present at the 2018 UBS Global Healthcare ConferenceCAMBRIDGE, Mass. and BEIJING, China, May 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the 2018 UBS Global Healthcare Conference in New York, NY. The presentation is scheduled for 10:30 AM ET on Wednesday, May 23, 2018. A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event. About BeiGene Investor Contact Media Contact i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation. |